NCT03971045View on ClinicalTrials.gov

Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

May 20, 2020

Primary Completion Date

December 1, 2024

Study Completion Date

March 1, 2025

Conditions
Breast CancerChest Wall Tumor
Interventions
DRUG

Pembrolizumab

Patients will be treated with pembrolizumab administered as an intravenous infusion at 200 mg in 21-day treatment cycles and oral cyclophosphamide (CTX) 50 mg per day in metronomic administration as a 21 days cycle

Trial Locations (1)

20141

RECRUITING

Istituto Europeo di Oncologia, Milan

All Listed Sponsors
lead

European Institute of Oncology

OTHER

NCT03971045 - Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer | Biotech Hunter | Biotech Hunter